PFKP encodes phosphofructokinase-platelet, a rate-limiting enzyme that catalyzes the phosphorylation of fructose 6-phosphate to fructose 1,6-bisphosphate in glycolysis 1. Beyond its primary enzymatic function, PFKP operates through both glycolysis-dependent and glycolysis-independent mechanisms, functioning in multiple cellular compartments including cytoplasm, membrane, mitochondria, lysosomes, and nucleus 2. PFKP expression is transcriptionally regulated by transcription factors such as TGF-β1/SMAD3-SP1 1, Zeb1 3, and c-Myc 4, and post-translationally stabilized by deubiquitinase USP5 5. The protein is frequently overexpressed across multiple cancer types including renal fibrosis 1, breast cancer 35, head and neck squamous cell carcinoma 4, and melanoma 6, where it promotes cell proliferation, metastasis, angiogenesis, and metabolic reprogramming. PFKP forms a positive feedback loop with c-Myc, enhancing tumor progression 4. Its overexpression correlates with poor patient prognosis across cancer types 645, making it a potential prognostic marker and therapeutic target. Selective targeting of PFKP shows promise for cancer therapy, particularly when combined with other metabolic inhibitors 64.